X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NOVARTIS AJANTA PHARMA/
NOVARTIS
 
P/E (TTM) x 20.7 349.6 5.9% View Chart
P/BV x 8.9 17.2 51.9% View Chart
Dividend Yield % 0.7 1.7 40.1%  

Financials

 AJANTA PHARMA   NOVARTIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
NOVARTIS
Mar-16
AJANTA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,720982 175.2%   
Low Rs1,103556 198.3%   
Sales per share (Unadj.) Rs194.6252.9 76.9%  
Earnings per share (Unadj.) Rs45.262.1 72.8%  
Cash flow per share (Unadj.) Rs50.363.3 79.5%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.61.3 43.6%  
Book value per share (Unadj.) Rs132.0363.6 36.3%  
Shares outstanding (eoy) m88.7731.96 277.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.0 238.5%   
Avg P/E ratio x31.212.4 252.2%  
P/CF ratio (eoy) x28.112.2 231.0%  
Price / Book Value ratio x10.72.1 505.4%  
Dividend payout %17.716.1 109.9%   
Avg Mkt Cap Rs m125,29924,580 509.8%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,5701,801 142.7%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m17,2758,083 213.7%  
Other income Rs m166829 20.1%   
Total revenues Rs m17,4428,913 195.7%   
Gross profit Rs m5,807234 2,479.6%  
Depreciation Rs m45137 1,227.8%   
Interest Rs m492 2,716.7%   
Profit before tax Rs m5,4741,025 534.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m1,460752 194.1%   
Profit after tax Rs m4,0141,986 202.1%  
Gross profit margin %33.62.9 1,160.2%  
Effective tax rate %26.773.4 36.4%   
Net profit margin %23.224.6 94.6%  
BALANCE SHEET DATA
Current assets Rs m7,63912,678 60.3%   
Current liabilities Rs m2,7152,433 111.6%   
Net working cap to sales %28.5126.7 22.5%  
Current ratio x2.85.2 54.0%  
Inventory Days Days4333 132.2%  
Debtors Days Days7922 349.8%  
Net fixed assets Rs m6,91469 9,991.0%   
Share capital Rs m177160 110.7%   
"Free" reserves Rs m11,44211,460 99.8%   
Net worth Rs m11,72111,621 100.9%   
Long term debt Rs m1490-   
Total assets Rs m14,81414,400 102.9%  
Interest coverage x112.9570.5 19.8%   
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 207.7%   
Return on assets %27.413.8 198.7%  
Return on equity %34.217.1 200.4%  
Return on capital %46.523.6 197.4%  
Exports to sales %55.10.7 7,404.9%   
Imports to sales %6.018.6 32.3%   
Exports (fob) Rs m9,52760 15,825.7%   
Imports (cif) Rs m1,0381,503 69.0%   
Fx inflow Rs m10,422186 5,594.1%   
Fx outflow Rs m1,6781,821 92.2%   
Net fx Rs m8,744-1,635 -534.9%   
CASH FLOW
From Operations Rs m3,2642,531 129.0%  
From Investments Rs m-2,093-8,270 25.3%  
From Financial Activity Rs m-1,186-386 307.4%  
Net Cashflow Rs m-15-6,125 0.2%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 2.0 77.5%  
FIIs % 7.6 1.6 475.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.5 79.1%  
Shareholders   20,968 41,647 50.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS